Cargando…
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
BACKGROUND: Despite regulatory efforts to formalize guidance policies on biosimilars, there remains a need to educate healthcare stakeholders on the acknowledged definition of biosimilarity and the data that underpin it. OBJECTIVES: The objectives of the study were to systematically collate publishe...
Autores principales: | Jacobs, Ira, Petersel, Danielle, Shane, Lesley G., Ng, Chee-Keng, Kirchhoff, Carol, Finch, Gregory, Lula, Sadiq |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126212/ https://www.ncbi.nlm.nih.gov/pubmed/27807766 http://dx.doi.org/10.1007/s40259-016-0199-9 |
Ejemplares similares
-
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016) -
Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2017) -
The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects
por: Declerck, Paul, et al.
Publicado: (2017) -
Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
por: Carrascosa, Jose-Manuel, et al.
Publicado: (2018) -
Drug tendering: drug supply and shortage implications for the uptake of biosimilars
por: Dranitsaris, George, et al.
Publicado: (2017)